May 19, 2026

Notice Regarding Distribution of Dividend from Surplus

(291K)

IR

Apr 30, 2026

Reason for the change in Representative Directors and Other Officers

(171K)

Other

Apr 30, 2026

Consolidated Financial Results Highlights for the Fiscal Year Ended March 31, 2026

(268K)

IR

Apr 30, 2026

Consolidated Financial Results Highlights 4Q 2025 (fiscal year ended March 31, 2026)

(634K)

IR

Apr 30, 2026

Notice Concerning Recording of Extraordinary Gain (Gain on Sale of Fixed Assets) and Extraordinary Loss (Impairment Loss)

(123K)

IR

Mar 12, 2026

Development of High-Purity and High-Bioavailability Lycopene, and Launch of Sample Distribution

Product / Tech

Sustainability